Spots Global Cancer Trial Database for erdafitinib
Every month we try and update this database with for erdafitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) | NCT06351371 | Malignant Solid... | Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | NCT04754425 | Castration-Resi... Castration-Resi... Metastatic Mali... Metastatic Pros... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Biopsy Biospecimen Col... Erdafitinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | NCT04172675 | Urinary Bladder... | Erdafitinib Investigator Ch... Investigator Ch... | 18 Years - | Janssen Research & Development, LLC | |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | NCT04963153 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... | Biospecimen Col... Computed Tomogr... Enfortumab Vedo... Erdafitinib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma | NCT02699606 | Neoplasm | Erdafitinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations | NCT04083976 | Advanced Solid ... | Erdafitinib | 6 Years - | Janssen Research & Development, LLC | |
| An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer | NCT02365597 | Urothelial Canc... | Erdafitinib Midazolam Metformin | 18 Years - | Janssen Research & Development, LLC | |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) | NCT06308822 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | NCT04917809 | Bladder Cancer Recurrent Bladd... FGFR3 Gene Muta... | Erdafitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| FGFR Inhibitor in FGFR Dysregulated Cancer | NCT03827850 | Lung Cancer NSCLC Pulmonary Neopl... Squamous Cell L... NSCLC Stage IV | ERDAFITINIB | 18 Years - | Lung Cancer Group Cologne | |
| FGFR Inhibitor in FGFR Dysregulated Cancer | NCT03827850 | Lung Cancer NSCLC Pulmonary Neopl... Squamous Cell L... NSCLC Stage IV | ERDAFITINIB | 18 Years - | Lung Cancer Group Cologne | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | NCT03473743 | Urothelial Carc... | Erdafitinib Cetrelimab Cisplatin Carboplatin | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | NCT03473743 | Urothelial Carc... | Erdafitinib Cetrelimab Cisplatin Carboplatin | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing | NCT06129084 | Metastatic Blad... Metastatic Urot... | FGFR Testing | 18 Years - | British Columbia Cancer Agency | |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | NCT05859334 | Recurrent Gliob... Recurrent WHO G... Recurrent WHO G... | Biospecimen Col... Erdafitinib Magnetic Resona... Optical Coheren... | 18 Years - | National Cancer Institute (NCI) | |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | NCT03999515 | Castration-Resi... Double-Negative... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Enzalutamide Erdafitinib | 18 Years - | University of Washington | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) | NCT06351371 | Malignant Solid... | Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers | NCT03547037 | Neoplasm | JNJ-63723283 Erdafitinib | 20 Years - | Janssen Pharmaceutical K.K. | |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | NCT03155620 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
